Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - June 2013

Advanced Portfolio Management for the Pharma and Biotech Industries

10 Jun 2013 - 12 Jun 2013 - Zurich, Switzerland

Bookmark and Share

In an era of declining R&D productivity and unprecedented loss of blockbuster patent exclusivity, the need to maximize the value of its core assets under ever constrained budgetary and human resources has never been more critical to the Pharmaceutical and Biotechnology industry. An integral part of strategic and business planning, the portfolio management process influences decisions that directly impact company fortunes — especially when advancing the right compounds under risk and uncertainty to create the potential for billions of dollars in long-term revenue.

Effective portfolio management requires foresight, discipline, preparation, and diligence, a serious challenge given the daily pressures faced by all organizations. Top-performing companies review, refresh, and execute their portfolio strategies on a continual basis through the application of excellent process, methodology, analysis, and decision making. For many organizations, however, numerous obstacles make it difficult to adopt a sustainably successful approach to portfolio management.

This Masterclass is your roadmap to maximizing portfolio value in accordance with management’s strategic and financial goals. Designed to improve companies’ abilities to progress compounds from the pre-clinical stage to commercial brand management, it showcases benchmarks and best practices for teams managing investments across the entire value chain – pre-clinical and clinical projects as well as marketed brand products.

The Masterclass will introduce the CREOPM™ Methodology, a unique, holistic framework for Portfolio Management developed by the trainer – Dr. Richard Bayney – President of Project & Portfolio Value Creation. Dr. Bayney, a 23-year veteran of the Pharmaceutical and Biotechnology industry, was Head of Strategic Planning at Bayer and Head of Portfolio Management & Decision Analysis at Bristol-Myers Squibb and Johnson & Johnson. CREOPM™ is an overarching Portfolio Management framework comprised of the following steps:

  • Categorize
  • Risk Analysis
  • Evaluate
  • Optimize
  • Prioritize
  • Manage


Reinforce your portfolio management strategy and enable execution with the CREOPM™ framework

Follow a step-by-step guide to improve strategic planning, create the criteria necessary to advance some projects while discontinuing others, and make the best use of constrained budgetary and human resources by maximizing strategic and financial value. Understand team members’ roles in portfolio analysis and how to influence executive decision-making irrespective of your hierarchical level within the organization.

Create nimble development strategies, boost revenues, and extend market exclusivity

Portfolio management of branded medicines stretches from discovery to patent expiration, so it is important to ensure that the transitions from drug discovery to clinical development, registration, and lifecycle management are relatively seamless through a carefully orchestrated ‘push-pull’ mechanism i.e. ‘push’ from discovery and ‘pull’ from commercial. Learn how to create investment options, enable efficient decision-making, analyze ROI, and continuously build equity by maximizing portfolio value under constrained budgetary and human resources.

Build portfolio management excellence

In a rapidly evolving and increasingly competitive business environment, every company must strive to make the best use of its constrained resources by furthering those assets which, despite their inherent risks and uncertainties, are likely to provide sustainable growth. Irrespective of whether a formal group oversees the portfolio management process, executives expect that the best data and information will be presented to them in order for logically consistent and defensible decisions to be made. Explore the different capabilities required to build portfolio management excellence, examine how budgets and human resources can best be utilized, and track the enhanced value of better decisionmaking processes. Finally, create an organizational culture in which every stakeholder sees himself/herself as a contributor to successful enterprise portfolio management.

The Masterclass begins with well-founded theory and quickly moves to practical implementation and executive decision-making based on the trainer’s expertise and experience with 3 major Pharmaceutical and Biotechnology companies (1996-2007) as well as consulting across several industry verticals (2008-present).

Dr. Bayney’s emphasis is on helping organizations move from portfolio value creation to portfolio value maximization by putting in place sequential building blocks to attain protracted excellence in portfolio management.

Further information
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos